Ampliphi Biosciences Corp., of San Diego, has filed to raise up to $12 million from the sale of shares of its common stock. It also intends to grant the underwriters a 30-day option to purchase additional shares. The offering has not yet been priced. The company is focused on the the development of targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections.